Journal
EUROPEAN JOURNAL OF ENDOCRINOLOGY
Volume 179, Issue 1, Pages R19-R29Publisher
BIOSCIENTIFICA LTD
DOI: 10.1530/EJE-17-0990
Keywords
-
Categories
Funding
- European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme [694913]
- Deutsche Forschungsgemeinschaft (DFG) [CRC/Transregio 205/1, RE 752/20-1]
- Else Kroner-Fresenius Stiftung [2013_A182, 2015_A171]
Ask authors/readers for more resources
The syndrome of primary aldosteronism (PA) is characterized by hypertension with excessive, autonomous aldosterone production and is usually caused by either a unilateral aldosterone-producing adenoma or bilateral adrenal hyperplasia. The diagnostic workup of PA is a sequence of three phases comprising screening tests, confirmatory tests and the differentiation of unilateral from bilateral forms. The latter step is necessary to determine the optimal treatment approach of unilateral laparoscopic adrenalectomy (for patients with unilateral PA) or medical treatment with a mineralocorticoid receptor antagonist (for patients with bilateral PA). Since the publication of the revised Endocrine Society guideline 2016, a number of key studies have been published. They challenge the recommendations of the guideline in some areas and confirm current practice in others. Herein, we present the recent developments and current approaches to the medical management of PA.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available